Mushroom Industry & Market Trends
$45.7B projected by 2034
Zion Market Research projects the global functional mushroom market at $45.66 billion by 2034, up from $16.90 billion in 2024. Four major research firms disagree sharply on the market's size today but agree closely on how fast it is growing.
Zion Market Research, Functional Mushroom Market report
8.8–11.2%
projected compound annual growth rate across four independent market research firms — a notably narrow band given how much they disagree on current market size
37%
of US consumers eat or drink functional mushroom foods and beverages, versus just over 25% who take mushroom supplements (Nutrition Business Journal, 2024)
36
randomized controlled trials on the six leading medicinal mushroom species published 2015–2024, against 5,424 total publications (PubMed)
Zion Market Research, Functional Mushroom Market report
View as image ↗Search for the size of the functional mushroom market and you will get four answers that appear to contradict each other. Mordor Intelligence measures $12.06 billion in 2025. Zion Market Research measures $16.90 billion in 2024. Fortune Business Insights measures $28.69 billion in 2023. Grand View Research measures $31.71 billion in the same year.
Then come the projections, which are the numbers that actually circulate: $20.74 billion by 2031 from Mordor, $45.66 billion by 2034 from Zion, $51.87 billion by 2030 from Fortune, $65.83 billion by 2030 from Grand View.
Most coverage picks one measured value and one projection from a different firm, sets them side by side, and presents the gap as analytical disagreement. It usually is not. It is a comparison between a measurement and a forecast, taken from firms using different scope definitions and different target years.
Reading the Numbers Correctly
The Firms Disagree About Today, Not About Growth
Each bar starts at the firm’s measured base-year value and ends at its forecast. Headlines usually compare a measured value from one firm against a forecast from another — which is where the “$12 billion vs. $66 billion” confusion comes from.
Spread on today’s size
~2.6× — $12.06B to $31.71B, depending on which segments are counted
Spread on growth rate
2.4 pts — 8.83% to 11.2% a year, a comparatively narrow band
Solid segment = the firm’s measured base-year value. Lighter segment = the additional value its forecast adds by the target year. Bars share one axis scaled to $70B. Base years and forecast years differ by firm and are labelled individually.
Sources: Mordor Intelligence, Zion Market Research, Fortune Business Insights, and Grand View Research functional mushroom market reports (commercial industry estimates, not peer-reviewed research).
Align the estimates properly and something more interesting appears. The firms disagree substantially about how big the market is right now — roughly a 2.6-fold spread — because they draw the category boundary in different places. But their growth rates cluster tightly, between 8.83% and 11.2% a year. Four organisations with different definitions, different data, and different commercial incentives arrived at nearly the same slope.
That agreement on slope is what makes the growth question worth asking. Market reports tell you the category is expanding; they rarely explain the mechanism. This article covers the second half of the analysis: the five forces actually driving functional mushroom demand, and how well the scientific evidence behind each one holds up.
For the full market size and scope breakdown, see The Functional Mushroom Market: Size, Growth, and Projections.
Key Takeaways
- Four major research firms project the functional mushroom market between $20.74 billion (2031) and $65.83 billion (2030); the widely quoted $45.66 billion figure is Zion Market Research's projection for 2034, not a current or 2030 value
- The firms disagree about today's market size by roughly 2.6× because of scope definitions, but their growth-rate projections cluster tightly between 8.83% and 11.2% annually
- The format shift into food and beverages is the clearest demand signal: 37% of US consumers eat or drink functional mushroom products versus just over 25% taking supplements, and mushroom-enhanced food and beverage sales exceeded $700 million in 2023 (Nutrition Business Journal)
- Mushroom bioactive metabolites with documented functional properties include polysaccharides, eritadenine, lignin, chitosan, mevinolin, and astrakurkurone (Ishara et al., 2022), with (1,3)(1,6)-β-D-glucans, triterpenes, phenolic compounds, and sterols characterised across the major commercial species (Łysakowska et al., 2023)
- Edible mushrooms as meat analogues represent a growth channel independent of supplement demand, supported by umami flavour, meaty texture, high protein, and status as the only vegetative source of vitamin D (Boro et al., 2025)
- The research base grew substantially — PubMed records for the six leading species more than doubled between 2005–2014 and 2015–2024 — but randomized controlled trials rose only from 27 to 36, meaning the commercial "backed by science" narrative rests largely on preclinical and review literature
Market Sizing
Is the mushroom market worth $45 billion today?
The claim
“The functional mushroom market is a $45 billion industry.”
Zion Market Research's $45.66 billion figure circulates widely without its date attached, and gets repeated as a present-day market size.
What research shows
MisleadingThe $45.66 billion figure is Zion Market Research's projection for 2034. The same report puts the 2024 measured value at $16.90 billion — under 40% of the headline number.
Measured present-day estimates from the four major firms range from $12.06 billion (Mordor, 2025) to $31.71 billion (Grand View, 2023). The category is real and growing at a rate all four firms agree on, but the headline figure describes a market roughly a decade away, and only if current growth rates hold.
Zion Market Research, Mordor Intelligence, Grand View Research, and Fortune Business Insights functional mushroom market reports
Growth Driver 1: Immune and Cognitive Health Demand
The most direct driver is consumer demand for immune and cognitive health products, which accelerated after 2020 and has not reversed.
Immune health was an established supplement category well before the pandemic, but the period produced a step-change in consumer awareness and spending on immune support that reshaped buying patterns. Functional mushrooms — particularly reishi for immune support and lion's mane for cognitive function — moved into mainstream retail during this window. Nutrition Business Journal's market analysis identifies reishi and lion's mane as the species drawing the most consumer attention, with lion's mane specifically tied to interest in mood and mental health.
There is a real molecular basis under the marketing. Ishara and colleagues (2022) reviewed mushroom bioactive metabolites studied in relation to diabetes, cardiovascular disease, hypertension, cancer, DNA damage, hypercholesterolemia, and obesity, identifying polysaccharides, eritadenine, lignin, chitosan, mevinolin, and astrakurkurone as the compounds with documented activity across diverse cellular and physiological pathways.[3] Łysakowska and colleagues (2023) characterised the compound profile across the six most commercially significant species — lion's mane, reishi, chaga, cordyceps, shiitake, and turkey tail — identifying (1,3)(1,6)-β-D-glucans classified as dietary fibre, along with triterpenes, phenolic compounds, and sterols.[4]
These are specific molecular species with characterised structures, not marketing abstractions. That distinction matters commercially: it is what allows functional mushroom products to make ingredient-level claims that survive scrutiny in a way that vaguer wellness categories cannot.
Growth Driver 2: The Shift Into Food and Beverages
The second driver is a format change: mushrooms moving out of capsules and into things people eat and drink.
This is where the demand signal is clearest. Nutrition Business Journal's 2024 consumer research found that 37% of US consumers eat or drink functional mushroom foods and beverages, compared with just over 25% who take functional mushroom supplements. Mushroom-enhanced functional food and beverage sales exceeded $700 million in 2023 — nearly double the supplement side of the category — while mushroom supplement sales have more than quadrupled since 2019.
The format reaches a different consumer than capsules do. Someone who would not add a supplement to their routine will buy a coffee blend or a protein drink that happens to contain mushroom extract. That widens the addressable market well beyond what supplement-sector projections capture, and it explains why the food and beverage segment carries so much weight in the more aggressive forecasts.
Yang and colleagues (2025) reviewed the scientific and biotechnological groundwork behind this shift, covering pharmacological work on medicinal mushrooms, advances in macrofungal cultivation, and the value-added products derived from them, with specific emphasis on the rapidly growing market for mushroom-based beverages and their positioning as functional foods.[6] Łysakowska and colleagues reached a similar conclusion from the food science side, describing medicinal mushrooms as having substantial potential in the design of innovative functional foods.[4]
The research literature tracks the commercial pivot closely. PubMed records combining the six leading species with functional-food or beverage terms rose from 49 in 2005–2014 to 279 in 2015–2024 — a 5.7-fold increase, faster than the growth in mushroom research overall.
Whether the extract doses in a typical mushroom coffee are high enough to produce measurable physiological effects is a separate question, and the answer varies considerably by product. The commercial success of the format is not in doubt; the pharmacological equivalence between a beverage serving and a studied dose frequently is.
Growth Driver 3: Mushrooms as Meat Analogues
The third driver runs independently of the supplement and wellness markets: the role of mushrooms in plant-based eating.
Boro and colleagues (2025) reviewed edible mushrooms as meat alternatives and set out why they fit the role — natural umami flavour, meaty texture, and high content of protein, essential amino acids, polysaccharides including β-glucan and chitin, vitamins, minerals, polyphenols, and antioxidants.[5] They also note that mushrooms are the only vegetative source of vitamin D, and situate the shift within the environmental case for meat alternatives, citing livestock's contribution to human-caused greenhouse gas emissions at up to 14.5%.
Boro et al. (2025) · Food Research International
- Population
- Comprehensive review of the nutritional, therapeutic, and market literature on edible mushrooms as meat alternatives
- Intervention
- Mushrooms as a primary ingredient in meat-analogue products
- Comparator
- Other plant-based protein sources
- Finding
- Mushrooms offer umami flavour, meaty texture, high protein and essential amino acids, β-glucan and chitin, and are the only vegetative source of vitamin D — but commercialisation faces scalability, cost-effectiveness, shelf-life stability, and consumer perception barriers.
preliminary A narrative review of compositional and market literature, not an experimental study. It establishes suitability and constraints, not consumer outcomes.
Boro et al. (2025), Food Research International 214:116632
Practical applications are already mainstream: king oyster as a pulled-pork substitute, lion's mane as a seafood analogue, shiitake as an umami base in plant-based burgers. These drive food service and retail demand with no health claim attached at all.
The segment's resilience is notable. The broader plant-based protein market cooled sharply after 2022, with major engineered-protein brands reporting sales declines. Mushrooms, positioned as a recognisable whole food rather than a processed protein isolate, have been less exposed to the consumer backlash against ultra-processed meat alternatives. Boro and colleagues are careful not to overstate the runway, flagging scalability, cost-effectiveness, shelf-life stability, and consumer perception as unresolved commercialisation challenges.[5]
Growth Driver 4: A Research Base That Is Growing — Unevenly
The fourth driver is the accumulating research literature itself, which both reflects and reinforces consumer demand. This is also the driver most often overstated, so it is worth being precise about what has actually grown.
What “Backed by Research” Actually Means
Publication Volume Doubled. Clinical Trials Did Not.
PubMed records for the six most commercially significant medicinal mushroom species, comparing 2005–2014 with 2015–2024. The research base did expand — but the fastest growth is in food and beverage framing, not in the controlled human trials that would settle whether the products work.
Medicinal mushroom + six major species, title/abstract
Same species set, restricted to functional-food or beverage terms
Same species set, PubMed publication type = RCT
The number that matters most is the smallest one. Thirty-six randomized controlled trials across ten years, spread over six species and dozens of health claims, is a thin base for a category selling at this scale.
All bars share one axis scaled to the largest count (5,424). The two smaller categories are genuinely small — the bars are not truncated.
Source: PubMed E-utilities record counts, retrieved August 2026. Species set: medicinal mushroom (general), Ganoderma lucidum, Hericium erinaceus, Lentinula edodes, Trametes versicolor, Inonotus obliquus, and Cordyceps. Counts reflect title/abstract matches and will drift slightly as records are indexed.
Searching PubMed for the six leading medicinal mushroom species returns 2,486 records for 2005–2014 and 5,424 for 2015–2024. The literature genuinely more than doubled. But the randomized controlled trial subset moved from 27 to 36 across the same comparison — thirty-six controlled human trials in a decade, spread across six species and dozens of distinct health claims.
That distribution matters. The growth in mushroom publishing is concentrated in mechanistic work, cell and animal studies, and review articles, not in the controlled human trials that would resolve whether a given product produces a given outcome at a given dose. Łysakowska and colleagues state the position directly: the detailed mechanisms by which medicinal mushrooms affect the human body still require long-term clinical studies to confirm their nutraceutical effects, their safety, and their dosage.[4]
- Cell and mechanistic studiescompleted
Extensive. Compound classes, receptor interactions, and signalling pathways are well characterised across the major species.
- Animal studiescompleted
Extensive across immune, metabolic, and neurological endpoints.
- Case reports and observational datacompleted
Available, including long-running clinical use in East Asian medical systems.
- Small human trialscurrent
36 randomized controlled trials across six species for 2015–2024. Mostly small, short, and heterogeneous in preparation and dose.
- Large, long-duration RCTsmissing
Largely absent. Few trials are powered or long enough to establish durable outcomes in general populations.
- Robust meta-analysesmissing
Limited by the small, heterogeneous trial base beneath them — pooling short trials of different preparations does not resolve the underlying uncertainty.
The mechanistic and preclinical foundation is genuinely strong, which is why ingredient-level claims hold up. The controlled human trial layer is thin, which is why outcome-level claims for specific products usually do not.
PubMed record counts (retrieved August 2026); Łysakowska et al. (2023), Molecules 28(14)
The compounding cycle is still real: findings increase awareness, awareness increases investment, investment funds more research. But an honest reading is that consumer trust is currently running ahead of the clinical evidence base rather than tracking it. That gap is the category's central commercial risk, because it is the kind that closes abruptly when a high-profile trial returns a null result.
Growth Driver 5: East-West Infrastructure Reaching Maturity
The fifth driver is structural: the trade and credibility infrastructure connecting Asian cultivation capacity to Western consumer markets.
Niego and colleagues (2021) identified this convergence explicitly as a market force, naming the popularity of eastern herbal medicines, preference for natural and organic food products, gut-health products, and a positive outlook toward sports nutrition as the converging trends supporting growth in the medicinal mushroom market.[2] Their review also gives a peer-reviewed market data point rather than a vendor one, projecting an increase of USD 13.88 billion in global medicinal mushroom market size between 2018 and 2022.
The cultivation base sits overwhelmingly in East Asia. China is by a wide margin the world's largest producer of edible mushrooms, with commonly cited estimates placing its share of global output above 70% — though published figures vary considerably by source and methodology, and most measure edible mushroom production overall rather than medicinal species specifically. Japan, South Korea, and Taiwan account for much of the remainder, and the traditional medicine systems in these countries supplied both the cultivation knowledge and the earliest clinical research programmes, including the lentinan and PSK approvals in Japan covered elsewhere in this cluster.
Chang and Wasser (2018) mapped how that research base translates commercially, describing the biomedical applications of medicinal mushrooms across five categories: dietary food, dietary supplement products, a class of mushroom pharmaceuticals, natural biocontrol agents, and cosmeceuticals.[1] That breadth is a large part of why market estimates diverge so much — a firm counting all five categories will land near Grand View's numbers, and one counting supplements will land near Mordor's.
What has changed most since 2018 is Western distribution. Functional mushroom products now sit in mainstream grocery chains rather than specialty health stores, supported by Amazon distribution, nationally distributed brands, and mushroom coffee at convenience stores. That retail infrastructure did not exist at scale a decade ago.
For the regional breakdown in detail, see Global Medicinal Mushroom Market: Regional Breakdown.
What These Drivers Mean for Market Durability
Five drivers operating at once produce more durable growth than one. Individual drivers can stall — supplement trends rotate, beverage categories saturate, plant-based eating has proven cyclical. When demand is arriving through five partly independent channels, a slowdown in any one is absorbed rather than fatal.
The honest tension is that projections reaching $45–65 billion assume current growth rates hold for another five to ten years. Category-level friction is already visible: industry reporting through 2025 and 2026 has described consolidation among smaller functional mushroom brands and softening in some US retail channels, after several years in which supplement sales more than quadrupled. Precise channel-level decline figures circulate widely but are difficult to source to published data, and are best treated as unverified.
The more durable risk is quality. Chang and Wasser flagged, in 2018, unresolved problems in the production, standardization, and safety of mushroom dietary supplement products — and those problems have not been solved by the category's growth.[1] A market whose credibility rests on documented bioactive compounds is exposed whenever products do not reliably contain them.
Category Risk
ModerateProduct standardization remains unresolved
Concern
Chang and Wasser identified production, standardization, and safety of mushroom dietary supplement products as critically important unsolved problems for the field. Products sold as the same species and dose can differ substantially in actual bioactive content depending on the part of the organism used, the growing substrate, and the extraction method.
What the research says
The compound-level science is sound; the manufacturing consistency is what varies. Third-party testing, disclosure of fruiting body versus mycelium-on-grain, and stated β-glucan content (rather than total polysaccharide) are the practical signals that a product matches what the research studied.
Particularly relevant for: Anyone selecting functional mushroom supplements on the basis of published research
What to do
Check whether a product discloses β-glucan content specifically, and which part of the organism was used — the research base attaches to those specifics, not to 'mushroom extract' generally.
Chang and Wasser (2018), International Journal of Medicinal Mushrooms 20(12):1121-1133
Forecast Conditions
What would have to happen for the high projections to land
What would it take for the functional mushroom market to actually reach $45–65 billion?
Sustained 9–11% annual growth for 5–10 more years
All four firms assume it. The measured base years show the category growing, but the forecasts extrapolate well beyond the observed window.
A controlled human trial base that catches up to consumer expectations
36 RCTs across six species for 2015–2024. Outcome-level claims currently outrun the evidence supporting them.
Manufacturing standardization across the category
Flagged as unsolved by Chang and Wasser in 2018 and still unresolved: β-glucan content, fruiting body versus mycelium, and extraction method vary widely between products.
The food and beverage format continuing to widen the buyer base
Already working — 37% of US consumers versus just over 25% for supplements, and $700M+ in 2023 food and beverage sales.
Consumer trust surviving contact with null results
The category's credibility is built on 'backed by science.' Its resilience to a high-profile negative trial has not yet been tested.
PubMed record counts (retrieved August 2026); Chang and Wasser (2018); Nutrition Business Journal (2024); Grand View Research, Zion, Fortune Business Insights, and Mordor Intelligence market reports
The structural drivers are real, documented, and mostly independent of one another. The projections built on top of them are extrapolations, and they carry the assumptions of the firms that produced them. Both things can be true: the category has genuine scientific foundations and genuine consumer demand, and the specific dollar figure in the headline is a forecast for 2034 rather than a description of the present.
For the US supplement market and the quality concerns affecting it, see Mushroom Supplement Sales in the US: Market Analysis. For the longer 2030 horizon, see The Functional Mushroom Market: $50B+ Projected by 2030.
The Bottom Line
The functional mushroom market is driven by five mechanisms: post-2020 immune and cognitive health demand, a format shift into foods and beverages, mushrooms' role as meat analogues in plant-based eating, an expanding research base, and mature East-West trade infrastructure. The four major research firms disagree about the category's current size by roughly 2.6× because they count different segments, but their growth projections cluster tightly at 8.83–11.2% annually. The widely quoted $45.66 billion figure is Zion Market Research's projection for 2034, not a present-day value — the same report measures $16.90 billion in 2024. The compound-level science is well documented, but the controlled human trial base is thin: 36 randomized controlled trials across the six leading species for 2015–2024, against 5,424 total publications.
Frequently Asked Questions
Sources & References
- 1RTHM-00946·Chang, Shu Ting et al. (2018). “Current and Future Research Trends in Agricultural and Biomedical Applications of Medicinal Mushrooms and Mushroom Products (Review)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 2RTHM-01414·Niego, Allen Grace et al. (2021). “Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value..” Journal of fungi (Basel.Study breakdown →PubMed →↩
- 3RTHM-01542·Ishara, Jackson et al. (2022). “Nutraceutical potential of mushroom bioactive metabolites and their food functionality..” Journal of food biochemistry.Study breakdown →PubMed →↩
- 4RTHM-00843·Łysakowska, Paulina et al. (2023). “Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review..” Molecules (Basel.Study breakdown →PubMed →↩
- 5RTHM-02059·Boro, Sibo et al. (2025). “Edible mushrooms as meat analogues: A comprehensive review of nutritional, therapeutic, and market potential..” Food research international (Ottawa.Study breakdown →PubMed →↩
- 6RTHM-02215·Yang, Jing-Ya et al. (2025). “Innovative applications of medicinal mushrooms in functional foods and nutraceuticals: a focus on health-boosting beverages..” Frontiers in cellular and infection microbiology.Study breakdown →PubMed →↩